Evaxion A/S Secures $81K Grant to Fuel AI-Immunology Breakthroughs in Cancer and Infectious Disease Treatments

Evaxion A/S Biotech is excited to announce a breakthrough funding round in which the company raised 81,000, underscoring both the confidence of our investors and the immense potential of our pioneering TechBio approach. At the core of Evaxion’s innovation is our AI-Immunology™ platform—a powerful, proprietary, and scalable suite of AI prediction models that decode the human immune system to inform the development of novel immunotherapies. This infusion of capital will be strategically allocated to accelerate the advancement of our clinical-stage oncology pipeline, driving forward the development of personalized vaccines that harness targeted immunomodulation to combat various cancers. Additionally, these funds will bolster our preclinical infectious disease pipeline, which targets bacterial and viral infections with significant unmet medical needs. By enhancing our research and development efforts, we aim to optimize our algorithms and further refine our vaccine candidates, ensuring they meet the high standards of safety and efficacy that patients deserve. This investment is a testament to our commitment to transforming patient outcomes by offering innovative, evidence-driven therapeutic solutions that are tailor-made for individual needs. As we continue to push the boundaries of AI and immunology, we remain steadfast in our vision of a future where diseases like cancer and severe infections are effectively managed and, ultimately, overcome. For more detailed insights into our journey, our AI-Immunology™ platform, and our evolving vaccine pipeline, we invite you to visit our website and engage with our breakthrough story in biotech innovation.